# Zhaohui Leng

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/zhaohui-leng/

## Facts

| Field | Value |
| --- | --- |
| Citations | 53 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 4 |
| i10-index | 3 |
| Last Known Institution | Jiujiang University |
| OpenAlex ID | https://openalex.org/A5030870029 |
| Works | 7 |

## Researcher papers

- [LPCAT1 promotes gefitinib resistance via upregulation of the EGFR/PI3K/AKT signaling pathway in lung adenocarcinoma](https://scholariq.org/papers/lpcat1-promotes-gefitinib-resistance-via-upregulation-of-the-egfr-pi3k-akt/)
- [Etoposide/platinum plus anlotinib for patients with transformed small-cell lung cancer from EGFR-mutant lung adenocarcinoma after EGFR-TKI resistance: a retrospective and observational study](https://scholariq.org/papers/etoposide-platinum-plus-anlotinib-for-patients-with-transformed-small-cell-lung-2/)
- [Immunotherapy-based therapy as a promising treatment for EGFR-mutant advanced non-small cell lung cancer patients after EGFR-TKI resistance](https://scholariq.org/papers/immunotherapy-based-therapy-as-a-promising-treatment-for-egfr-mutant-advanced/)
- [Aumolertinib challenge as an optional treatment in advanced non small‑cell lung cancer after osimertinib failure with epidermal growth factor receptor‑sensitive mutation: A case series](https://scholariq.org/papers/aumolertinib-challenge-as-an-optional-treatment-in-advanced-non-small-cell-lung/)
- [A novel prednisone premedication protocol significantly decreases infusion‑related reactions of rituximab in newly diagnosed diffuse large B‑cell lymphoma](https://scholariq.org/papers/a-novel-prednisone-premedication-protocol-significantly-decreases-infusion/)
- [Anlotinib maintenance following adjuvant chemotherapy in newly diagnosed stage III–IV patients with epithelial ovarian cancer: a retrospective study](https://scholariq.org/papers/anlotinib-maintenance-following-adjuvant-chemotherapy-in-newly-diagnosed-stage/)
- [Etoposide/platinum plus anlotinib for patients with transformed small-cell lung cancer from EGFR-mutant lung adenocarcinoma after EGFR-TKI resistance: A retrospective and observational study](https://scholariq.org/papers/etoposide-platinum-plus-anlotinib-for-patients-with-transformed-small-cell-lung/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [GaN-based semiconductor devices and materials](https://scholariq.org/topics/gan-based-semiconductor-devices-and-materials/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)

## Researcher university

- [Jiujiang University](https://scholariq.org/institutions/jiujiang-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.